These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 31815649

  • 1. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M.
    Arthritis Res Ther; 2019 Dec 09; 21(1):272. PubMed ID: 31815649
    [Abstract] [Full Text] [Related]

  • 2. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
    Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J.
    Arthritis Res Ther; 2019 Dec 02; 21(1):263. PubMed ID: 31791386
    [Abstract] [Full Text] [Related]

  • 3. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
    Strand V, Tundia N, Bergman M, Ostor A, Durez P, Song IH, Enejosa J, Schlacher C, Song Y, Fleischmann R.
    Rheumatology (Oxford); 2021 Dec 01; 60(12):5583-5594. PubMed ID: 33590829
    [Abstract] [Full Text] [Related]

  • 4. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, Song Y, Wright GC.
    Arthritis Res Ther; 2022 Jun 24; 24(1):155. PubMed ID: 35751108
    [Abstract] [Full Text] [Related]

  • 5. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
    Strand V, Tundia N, Wells A, Buch MH, Radominski SC, Camp HS, Friedman A, Suboticki JL, Dunlap K, Goldschmidt D, Bergman M.
    Rheumatology (Oxford); 2021 Jul 01; 60(7):3209-3221. PubMed ID: 33313898
    [Abstract] [Full Text] [Related]

  • 6. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR.
    Arthritis Res Ther; 2018 Jun 19; 20(1):129. PubMed ID: 29921318
    [Abstract] [Full Text] [Related]

  • 7. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
    Strand V, Kaine J, Alten R, Wallenstein G, Diehl A, Shi H, Germino R, Murray CW.
    Arthritis Res Ther; 2020 Oct 15; 22(1):243. PubMed ID: 33059710
    [Abstract] [Full Text] [Related]

  • 8. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
    Strand V, Mease PJ, Soriano ER, Kishimoto M, Salvarani C, Saffore CD, Zueger P, McDearmon-Blondell E, Kato K, Gladman DD.
    Rheumatol Ther; 2021 Dec 15; 8(4):1789-1808. PubMed ID: 34636026
    [Abstract] [Full Text] [Related]

  • 9. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V, Kosinski M, Chen CI, Joseph G, Rendas-Baum R, Graham NM, van Hoogstraten H, Bayliss M, Fan C, Huizinga T, Genovese MC.
    Arthritis Res Ther; 2016 Sep 06; 18(1):198. PubMed ID: 27600829
    [Abstract] [Full Text] [Related]

  • 10. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Bingham CO, Walker D, Nash P, Lee SJ, Ye L, Hu H, Khalid JM, Combe B.
    Arthritis Res Ther; 2022 Jan 03; 24(1):11. PubMed ID: 34980223
    [Abstract] [Full Text] [Related]

  • 11. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
    Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R.
    RMD Open; 2017 Jan 03; 3(1):e000416. PubMed ID: 28326189
    [Abstract] [Full Text] [Related]

  • 12. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V, Kremer JM, Gruben D, Krishnaswami S, Zwillich SH, Wallenstein GV.
    Arthritis Care Res (Hoboken); 2017 Apr 03; 69(4):592-598. PubMed ID: 27565000
    [Abstract] [Full Text] [Related]

  • 13. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
    Strand V, Kremer J, Wallenstein G, Kanik KS, Connell C, Gruben D, Zwillich SH, Fleischmann R.
    Arthritis Res Ther; 2015 Nov 04; 17():307. PubMed ID: 26530039
    [Abstract] [Full Text] [Related]

  • 14. Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2.
    Strand V, Van den Bosch F, Ranza R, Leung YY, Drescher E, Zueger P, Saffore CD, Lertratanakul A, Lippe R, Nash P.
    Rheumatol Ther; 2021 Dec 04; 8(4):1827-1844. PubMed ID: 34661885
    [Abstract] [Full Text] [Related]

  • 15. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M, Takeuchi T, Fleischmann R, Gaich CL, DeLozier AM, Schlichting D, Kuo WL, Won JE, Carmack T, Rooney T, Durez P, Shaikh S, Hidalgo RP, van Vollenhoven R, Zerbini CAF.
    Arthritis Res Ther; 2017 Sep 18; 19(1):208. PubMed ID: 28923098
    [Abstract] [Full Text] [Related]

  • 16. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME.
    Ann Rheum Dis; 2017 Nov 18; 76(11):1853-1861. PubMed ID: 28798049
    [Abstract] [Full Text] [Related]

  • 17. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
    Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, Wang C, Cappelleri JC, Hendrikx T, Hsu MA.
    RMD Open; 2019 Nov 18; 5(1):e000806. PubMed ID: 30713721
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS.
    Lancet; 2018 Jun 23; 391(10139):2503-2512. PubMed ID: 29908669
    [Abstract] [Full Text] [Related]

  • 19. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
    Li Z, An Y, Su H, Li X, Xu J, Zheng Y, Li G, Kwok K, Wang L, Wu Q.
    Int J Rheum Dis; 2018 Feb 23; 21(2):402-414. PubMed ID: 29314645
    [Abstract] [Full Text] [Related]

  • 20. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
    Bartlett SJ, Bingham CO, van Vollenhoven R, Murray C, Gruben D, Gold DA, Cella D.
    Arthritis Res Ther; 2022 Apr 05; 24(1):83. PubMed ID: 35382883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.